Literature DB >> 15516342

Engaged and bystander T cell receptors are down-modulated by different endocytotic pathways.

Alicia Monjas1, Andrés Alcover, Balbino Alarcón.   

Abstract

T cell antigen receptor (TCR) engagement by stimulatory antibodies or its major histocompatibility complex-antigen ligand results in its down-modulation from the cell surface, a phenomenon that is thought to play a role in T cell desensitization. However, TCR engagement results in the down-modulation not only of the engaged receptors but also of non-engaged bystander TCRs. We have investigated the mechanisms that mediate the down-modulation of engaged and bystander receptors and show that co-modulation of the bystander TCRs requires protein-tyrosine kinase activity and is mediated by clathrin-coated pits. In contrast, the down-modulation of engaged TCRs is independent of protein-tyrosine kinases and clathrin pits, suggesting that this process is mediated by an alternate mechanism. Indeed, down-modulation of engaged TCRs appears to depend upon lipid rafts, because cholesterol depletion with methyl-beta-cyclodextrin completely blocks this process. Thus, two independent pathways of internalization are involved in TCR down-modulation and act differentially on directly engaged and bystander receptors. Finally, we propose that although both mechanisms coexist, the predominance of one or the other mechanisms will depend on the dose of ligand.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516342     DOI: 10.1074/jbc.M409342200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Dynamin 2-dependent endocytosis sustains T-cell receptor signaling and drives metabolic reprogramming in T lymphocytes.

Authors:  Tim Willinger; Matthew Staron; Shawn M Ferguson; Pietro De Camilli; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Have we become overly reliant on lipid rafts? Talking Point on the involvement of lipid rafts in T-cell activation.

Authors:  Anne K Kenworthy
Journal:  EMBO Rep       Date:  2008-06       Impact factor: 8.807

3.  Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.

Authors:  Georgios Vlasakakis; Antonella Napolitano; Ruth Barnard; Kim Brown; Jonathan Bullman; David Inman; Bart Keymeulen; David Lanham; Quentin Leirens; Alexander MacDonald; Enrica Mezzalana; Kevin Page; Minesh Patel; Caroline O Savage; Stefano Zamuner; Andre van Maurik
Journal:  Br J Clin Pharmacol       Date:  2019-02-05       Impact factor: 4.335

Review 4.  Taming the Triskelion: Bacterial Manipulation of Clathrin.

Authors:  Eleanor A Latomanski; Hayley J Newton
Journal:  Microbiol Mol Biol Rev       Date:  2019-02-27       Impact factor: 11.056

Review 5.  Rabs set the stage for polarity.

Authors:  Sara S Parker; Christopher Cox; Jean M Wilson
Journal:  Small GTPases       Date:  2017-01-27

6.  β-Arrestin-1 mediates the TCR-triggered re-routing of distal receptors to the immunological synapse by a PKC-mediated mechanism.

Authors:  Elena Fernández-Arenas; Enrique Calleja; Nadia Martínez-Martín; Severine I Gharbi; Rosana Navajas; Noel García-Medel; Petronila Penela; Antonio Alcamí; Federico Mayor; Juan P Albar; Balbino Alarcón
Journal:  EMBO J       Date:  2014-02-06       Impact factor: 11.598

7.  Arrestin makes T cells stop and become active.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  EMBO J       Date:  2014-02-06       Impact factor: 11.598

8.  Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.

Authors:  Serina Ortiz; Wenhui Lee; David Smith; Stephen J Forman; Terry D Lee; Chih-Pin Liu
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

9.  Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster.

Authors:  Santosha Vardhana; Kaushik Choudhuri; Rajat Varma; Michael L Dustin
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

10.  Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.

Authors:  Tanaya Vaidya; Robert M Straubinger; Sihem Ait-Oudhia
Journal:  Pharm Res       Date:  2018-03-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.